Patents Assigned to Fuso Pharmaceutical Industries, Ltd.
-
Patent number: 9096878Abstract: The present inventors conducted dedicated studies and successfully constructed expression vectors that enable high-level production of foreign gene-derived proteins in mammalian host cells, which comprise a translation-impaired dihydrofolate reductase gene cistron whose expression has been attenuated by altering the codons to the least frequently used codons in mammals; and a gene cassette which has a cloning site for incorporation of a foreign gene between a highly transcriptionally active promoter and a highly stable polyadenylation signal.Type: GrantFiled: December 22, 2009Date of Patent: August 4, 2015Assignees: National University Corporation Hokkaido University, Fuso Pharmaceutical Industries, Ltd.Inventors: Hiroshi Tahara, Yusuke Suzuki, Keiichi Yamamoto, Yuzuru Kitahara, Yasuhiko Suzuki
-
Publication number: 20150184230Abstract: An objective of the present invention is to provide the cytolethal distending toxin (CDT) of C. hyointestinalis and polynucleotides encoding it, and novel methods for detection of C. hyointestinalis using the cdt genes. The present inventors focused on the cytolethal distending toxin (CDT) of Campylobacter bacteria, and detected the cdt genes of a Campylobacter-like bacterium isolated from an enteritis patient in Thailand. The present inventors discovered a bacterial strain whose cdtB gene was amplified by common primers in C. jejuni, C. coli, and C. fetus, but not by multiplex PCR that can specifically detect the cdtA, cdtB, and cdtC genes of the three bacterial species. The bacterial strain was identified as C. hyointestinalis by 16S rRNA gene analysis. Furthermore, the entire nucleotide sequence of the cdt genes was determined by genome walking upstream and downstream of the cdtB gene.Type: ApplicationFiled: October 11, 2013Publication date: July 2, 2015Applicants: FUSO PHARMACEUTICAL INDUSTRIES, LTD., Osaka Prefecture University Public CorporationInventors: Shinji YAMASAKI, Worada SAMOSORUNSUK, Masahiro ASAKURA
-
Publication number: 20150147447Abstract: The present invention has demonstrated that microorganisms present in a liver can be killed by washing the bile duct and the portal vein with hot water, and then disinfecting the liver using a chlorine-based disinfectant. It has also been demonstrated that sterilizing effects can be enhanced by freezing the liver after disinfection with a chlorine-based disinfectant.Type: ApplicationFiled: May 31, 2013Publication date: May 28, 2015Applicant: Fuso Pharmaceutical Industries, Ltd.Inventors: Shinji Yamasaki, Atsushi Hinenoya, Iwao Morikochi, Mamoru Yamaguchi, Yukitoshi Sakuramoto, Kazumasa Nishida, Masahiro Asakura
-
Patent number: 9029627Abstract: A lentiviral vector was used to produce non-human animals that express human sFLT1 specifically in the murine placenta, to provide model animals of diseases such as pregnancy-induced hypertension syndrome that are close to the clinical conditions, methods for producing the model animals, methods of screening for candidate compounds as therapeutic agents for diseases such as pregnancy-induced hypertension syndrome by using the model animals, and therapeutic agents for diseases such as pregnancy-induced hypertension syndrome. As a result, the model animals were found to exhibit symptoms that are very close to the clinical conditions in human, which are presentation of hypertension as well as placental insufficiency, intrauterine growth retardation, glomerulosclerosis, and proteinuria during pregnancy, and improvement of those symptoms postpartum.Type: GrantFiled: March 4, 2011Date of Patent: May 12, 2015Assignees: Fuso Pharmaceutical Industries, Ltd.Inventors: Masaru Okabe, Masahito Ikawa, Tadashi Kimura, Keiichi Kumasawa
-
Patent number: 9018354Abstract: An objective of the present invention is to provide methods of producing human collagen molecules that are easy to isolate and purify and that have a structure substantially equivalent to that of a natural collagen molecule, wherein host cells that are transduced with a collagen gene synthesize large amounts of human collagen protein derived from a gene introduced into a high exogenous gene expression vector. Another objective of the present invention is to provide collagen molecules produced by the production methods. The present inventors discovered that a large amount of human collagen hardly contaminated with host cell-derived collagen could be produced, by selecting from various mammalian cells a host cell that has low collagen expression and introducing a collagen gene construct into a vector capable of high exogenous gene expression.Type: GrantFiled: March 31, 2006Date of Patent: April 28, 2015Assignees: Fuso Pharmaceutical Industries, Ltd., Osaka Prefectural GovernmentInventors: Tetsuo Kase, Akio Kimura, Hiroshi Ueyama, Mizuki Nishihara, Yoko Kisaki, Aya Keshi
-
Patent number: 8950027Abstract: A respiratory tract widening tool capable of reliably managing a respiratory tract in a supine posture and freely changing the posture, and a respiratory tract widening unit provided therewith are provided.Type: GrantFiled: December 21, 2010Date of Patent: February 10, 2015Assignees: Fuso Pharmaceutical Industries, Ltd., NextierInventors: Keiichi Yamamoto, Yuzuru Kitahara, Yasuyo Maruyama, Toru Shinzato
-
Patent number: 8932867Abstract: The present invention provides a high purity heparin useful to be a pharmaceutical product, cosmetics, research reagent, or the like, and a method for producing the same, more specifically, a heparin which does not substantially contain a nitrous acid degradation-resistant impurity and a method for producing a heparin, comprising mixing an aqueous solution of 5 to 30% by weight of the heparin with ethanol having an amount (volume) 0.2 to 1 times the amount (volume) of the aqueous heparin solution to obtain a colloidal precipitate of heparin.Type: GrantFiled: September 13, 2011Date of Patent: January 13, 2015Assignees: University of Miyazaki, Fuso Pharmaceutical Industries Ltd.Inventors: Michio Muguruma, Hiroshi Murata
-
Publication number: 20140370602Abstract: The present inventors discovered that genes could be introduced specifically into trophectodermal cells with high efficiency, by infecting blastocysts with viral vectors carrying an arbitrary polynucleotide, or by using a nucleic acid transfection reagent in blastocysts, from which zona pellucida (extracellular matrix covering preimplantation early embryos to protect them from infection of viruses and the like) is removed. This method has no risk of infecting cells of the inner cell mass, which develops into a fetus in the future, with the introduced polynucleotide because the trophectoderm serves as a barrier. The present invention provides methods for introducing foreign genes into only placenta but not fetus, which enables rescue of genetically mutant animals from embryonic lethality due to placental abnormality and allows their birth. Furthermore, it is possible to analyze expression and effect of genes that regulate placental formation or placental function by using these methods.Type: ApplicationFiled: July 16, 2014Publication date: December 18, 2014Applicants: FUSO PHARMACEUTICAL INDUSTRIES, LTD.Inventors: Masaru OKABE, Masahito IKAWA
-
Publication number: 20140335198Abstract: The invention relates to a stable bicarbonate ion-containing drug solution, particularly a bicarbonate-containing drug solution for dialysis in which the stability has been improved by the presence of a phosphate ion. Further, the invention relates to a drug solution for acute blood purification, particularly a dialysate and a substitution liquid for acute blood purification to be mixed before use containing the drug solution. Still further, the invention relates to a dialysate and a substitution liquid for acute blood purification to be mixed before use in which the formation of insoluble fine particles or precipitates is prevented for a long time after mixing and with which hypokalemeia and hypophosphatemia are not caused.Type: ApplicationFiled: May 7, 2014Publication date: November 13, 2014Applicants: NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITY, FUSO PHARMACEUTICAL INDUSTRIES, LTD.Inventors: Shigeto ODA, Tomohito SADAHIRO, Masataka NAKAMURA, Syuichi TANAKA, Shogo TOKUOKA, Hiroya OTANI
-
Publication number: 20140315322Abstract: The present invention relates to providing a simple and highly reproducible method for measuring the concentration of acetic acid in blood plasma by using a gas chromatography/mass spectrometry (GC/MS), and more specifically relates to a method for measuring the concentration of acetic acid in blood plasma by using a gas chromatography/mass spectrometry (GC/MS), which comprises extracting acetic acid in blood plasma with methyl-tert-butyl ether (MTBE).Type: ApplicationFiled: December 26, 2012Publication date: October 23, 2014Applicant: FUSO PHARMACEUTICAL INDUSTRIES, LTD.Inventors: Shigeaki Yagi, Manabu Nishizawa, Hidetoshi Matsuzawa, Hideo Nagase
-
Patent number: 8815598Abstract: The present inventors discovered that genes could be introduced specifically into trophectodermal cells with high efficiency, by infecting blastocysts with viral vectors carrying an arbitrary polynucleotide, or by using a nucleic acid transfection reagent in blastocysts, from which zona pellucida (extracellular matrix covering preimplantation early embryos to protect them from infection of viruses and the like) is removed. This method has no risk of infecting cells of the inner cell mass, which develops into a fetus in the future, with the introduced polynucleotide because the trophectoderm serves as a barrier. The present invention provides methods for introducing foreign genes into only placenta but not fetus, which enables rescue of genetically mutant animals from embryonic lethality due to placental abnormality and allows their birth. Furthermore, it is possible to analyze expression and effect of genes that regulate placental formation or placental function by using these methods.Type: GrantFiled: July 31, 2006Date of Patent: August 26, 2014Assignees: Fuso Pharmaceutical Industries, Ltd.Inventors: Masaru Okabe, Masahito Ikawa
-
Patent number: 8771749Abstract: The invention relates to a stable bicarbonate ion-containing drug solution, particularly a bicarbonate-containing drug solution for dialysis in which the stability has been improved by the presence of a phosphate ion. Further, the invention relates to a drug solution for acute blood purification, particularly a dialysate and a substitution liquid for acute blood purification to be mixed before use containing the drug solution. Still further, the invention relates to a dialysate and a substitution liquid for acute blood purification to be mixed before use in which the formation of insoluble fine particles or precipitates is prevented for a long time after mixing and with which hypokalemeia and hypophosphatemia are not caused.Type: GrantFiled: October 6, 2008Date of Patent: July 8, 2014Assignees: National University Corporation Chiba University, Fuso Pharmaceutical Industries, Ltd.Inventors: Shigeto Oda, Tomohito Sadahiro, Masataka Nakamura, Syuichi Tanaka, Shogo Tokuoka, Hiroya Otani
-
Patent number: 8653249Abstract: The present inventors successfully constructed expression vectors that enable high-level production of foreign gene-derived proteins in mammalian host cells, which comprise a translation-impaired drug resistance gene cistron whose expression has been attenuated by altering the codons to the least frequently used codons in mammals; and a gene cassette which has a cloning site for incorporation of a foreign gene between a highly transcriptionally active promoter and a highly stable polyadenylation signal.Type: GrantFiled: February 27, 2009Date of Patent: February 18, 2014Assignees: Fuso Pharmaceutical Industries, Ltd., National University Corporation Hokkaido UniversityInventors: Yasuhiko Suzuki, Keiichi Yamamoto, Hiroshi Tahara, Yusuke Suzuki
-
Patent number: 8609606Abstract: Disclosed is a polypeptide of use in the development of reagents or medicines favourable to application for prevention or treatment of ischemic disorders such as conditions caused by ateriosclerosis. The polypeptide has at least one part containing an amino acid of sequence ID 1, and also enhances expression levels of the amino acid in mammalian blood vessels removed from ischemic conditions by means of blood reperfusion.Type: GrantFiled: March 4, 2011Date of Patent: December 17, 2013Assignee: Fuso Pharmaceutical Industries, Ltd.Inventors: Nobutaka Wakamiya, Katsuki Otani
-
Patent number: 8604162Abstract: Provided are isolated collectin (CL-L2s) genes including a base sequence set out in SEQ ID NO: 1, 3, 5, 7, 9, 12, 36, 38 or 40 relating to a novel collectin which are expected to exhibit an antibacterial activity, an antiviral activity and the like particularly in a human body; and isolated collectin proteins including an amino acid sequence set out in SEQ ID NO: 2, 4, 6, 8, 10, 13, 37, 39 or 41 and derivatives and fragments thereof.Type: GrantFiled: June 14, 2011Date of Patent: December 10, 2013Assignee: Fuso Pharmaceutical Industries, Ltd.Inventors: Nobutaka Wakamiya, Katsuki Ohtani, Takashi Sakamoto, Yuichiro Kishi
-
Patent number: 8586327Abstract: An objective of the present invention is to provide the cytolethal distending toxin (CDT) of C. hyointestinalis and polynucleotides encoding it, and novel methods for detection of C. hyointestinalis using the cdt genes. The present inventors focused on the cytolethal distending toxin (CDT) of Campylobacter bacteria, and detected the cdt genes of a Campylobacter-like bacterium isolated from an enteritis patient in Thailand. The present inventors discovered a bacterial strain whose cdtB gene was amplified by common primers in C. jejuni, C. coli, and C. fetus, but not by multiplex PCR that can specifically detect the cdtA, cdtB, and cdtC genes of the three bacterial species. The bacterial strain was identified as C. hyointestinalis by 16S rRNA gene analysis. Furthermore, the entire nucleotide sequence of the cdt genes was determined by genome walking upstream and downstream of the cdtB gene.Type: GrantFiled: August 29, 2008Date of Patent: November 19, 2013Assignees: Osaka Prefecture University, Fuso Pharmaceutical Industries, Ltd.Inventors: Shinji Yamasaki, Worada Samosorunsuk, Masahiro Asakura
-
Patent number: 8563743Abstract: Provided is a novel compound having an effective anti-cancer activity. The novel compound according to the present invention includes a compound represented by formula (I): [wherein R1 represents an alkoxyalkyl group having 2 to 6 carbon atoms] or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 17, 2011Date of Patent: October 22, 2013Assignee: Fuso Pharmaceutical Industries, Ltd.Inventors: Yoshitaka Ohishi, Takao Toda, Seiichi Takeda
-
Publication number: 20130230918Abstract: Novel collectin related molecules i.e., a novel collectin gene comprising a nucleotide sequence set out in SEQ ID NO: 1, and a novel collectin comprising an amino acid sequence set out in SEQ ID NO: 2, which are expected to exhibit anti-bacterial, anti-viral activity or the like especially in human body, and methods in which these molecules are used are provided.Type: ApplicationFiled: February 10, 2012Publication date: September 5, 2013Applicant: FUSO PHARMACEUTICAL INDUSTRIES, LTD.Inventor: Nobutaka Wakamiya
-
Publication number: 20130183764Abstract: The present invention provides a high purity heparin useful to be a pharmaceutical product, cosmetics, research reagent, or the like, and a method for producing the same, more specifically, a heparin which does not substantially contain a nitrous acid degradation-resistant impurity and a method for producing a heparin, comprising mixing an aqueous solution of 5 to 30% by weight of the heparin with ethanol having an amount (volume) 0.2 to 1 times the amount (volume) of the aqueous heparin solution to obtain a colloidal precipitate of heparin.Type: ApplicationFiled: September 13, 2011Publication date: July 18, 2013Applicants: FUSO PHARMACEUTICAL INDUSTRIES, LTD., UNIVERSITY OF MIYAZAKIInventors: Michio Muguruma, Hiroshi Murata
-
Patent number: D731647Type: GrantFiled: July 9, 2013Date of Patent: June 9, 2015Assignees: FUSO PHARMACEUTICAL INDUSTRIES, LTD., 3-D MATRIX, LTD.Inventors: Fukumitsu Nishioka, Shoujirou Tanioka, Masahiro Nohara, Kiyoshi Takano